In contrast, tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib, cabozantinib) and anti‐VEGF therapies (bevacizumab, ramucirumab) appear to exert efficacy largely independent of aetiology, suggesting that their mechanisms of action may bypass immune‐related resistance observed in MASLD.42 Here, VEGFA is linked to metabolic dysfunction-associated steatotic liver disease.